Our mission is to provide accessible outsourcing opportunities without sacrificing quality.
USA FDA 503A compounding facility with formulation and end-to-end clinical trial solutions.
Whether your project is an academic research or IP still in research, we’re committed to assisting and supporting your project with the right outcome.
Optimized & Dedicated access
Now offering formulation, testing, and dispensing capabilities
Investigational Drug Service
Clinical Trials & Investigational Drug Services
Specialized Pharmacy Support for Academic and Industry-Sponsored Research
UCRx supports clinical research programs through customized investigational drug preparation, sourcing coordination, dosage-form development, blinded and placebo-controlled preparations, packaging, labeling, dispensing and drug accountability.
Our pharmacists collaborate with principal investigators, study coordinators and institutional investigational drug service teams to develop pharmacy workflows aligned with approved study protocols.
Core capabilities
-
Investigational drug sourcing and formulation support
-
Placebo preparation, blinding and randomization support
-
Patient-specific investigational preparations
-
Sterile and nonsterile dosage-form compounding
-
Packaging, labeling and shipment coordination
-
Drug accountability, reconciliation and documented disposition
-
Coordination of analytical, stability and microbiological testing with qualified laboratories
From protocol planning to study completion, UCRx provides a dedicated pharmacy partner for complex research programs.
Services depend on applicable regulatory authorizations, study protocols, pharmacy licensure and approved quality procedures.
Every trial begins with a pharmacy consultant
Clinical Trial Drug Sourcing
Testing & Validation
Service
Outcomes
Access to big 3 national distributors for brand and generics.
Access to big 3 national distributors for Active Pharmaceutical Ingredients (APIs)
Onsite formulatio and compound all dosage forms when not available.
Lean Six-Sigma methodology applied to each production
Collaborate with FDA registered, DEA registered, and ISO 17025:2005 accredited for GMP and nonGMP testings
Method Development and Validation
Method Suitability Test
Sterility Method Suitability
Stability-Indicating Assay Study program.
USP compliant batch release testing programs
Pharmacist 24/7 On-Call
Emergency unblinding access
Telepharmacy patient consultation
Direct dispensing to patient or investigators
IP Return & reconcilcation
IP Destruction Service
Protocol Management & Randomization control.
Each clinical trial is driven by an in-house project manager.
Shipping and Dispensing with traceability.
End-to-End Project Management
Clinical Trial Drug Sourcing leverages USA Big 3 Drug distribution relationships to source drugs or APIs
Exceptional Access
broad access to the drugs a trial needs, anywhere in the USA
continuous supply throughout the course of a trial
competitive pricing through drug wholesaling contracting
track-and-trace compliant
The Role of Certified Research Pharmacists at UCRx in Clinical Trials
Certified research pharmacists at UCRx are pivotal in the execution of clinical trials, serving as both scientific experts and operational specialists. They design and compound blinded drug formulations, meticulously tailored to the unique demands of each study. By ensuring the integrity and stability of investigational drugs, these pharmacists uphold the rigorous standards required for clinical research while maintaining the critical blinding necessary to ensure unbiased results.
Through their expertise in formulation science, regulatory compliance, and quality assurance, UCRx pharmacists play an indispensable role in advancing clinical research. Their behind-the-scenes contributions help facilitate the development of innovative therapies, ultimately improving patient care and driving medical progress.
Investigational Drug Program at Universal Compounding Pharmacy
Decentralized Clinical Trials: Advancing New Therapies and Repurposing Existing Drugs
Henry Truong, PharmD, MS, serves as the Director of Investigational Drugs at Mariner Advanced Pharmacy in Redwood City and Universal Compounding Pharmacy in Signal Hill, CA. Since founding these pharmacies in 2011 and 2019 respectively, Dr. Truong has been instrumental in expanding their scope, transitioning from compounding pharmacist roles to launching and leading the Investigational Drug Service (IDS) division.
Dr. Truong’s pathway to becoming a research pharmacist evolved naturally through his early clinical experiences, which introduced him to investigational drug services. Collaborating with local academic researchers and supporting community patients further solidified his passion for advancing clinical trials. Today, he partners with prominent academic institutions and pharmaceutical companies to support clinical research.
Click here to explore sample trial projects.
Dr. Truong has contributed to numerous phase 1 and 2 trials alongside esteemed researchers. Among these, a groundbreaking trial investigates jacifusen, a novel drug aimed at treating a rare form of ALS in patients with the FUS gene mutation. This experimental therapy is delivered directly into the intrathecal space to target the disease at its source.
Phase 1 clinical trials, or early-phase studies, mark the initial testing of experimental drugs or treatments in human subjects. These trials prioritize safety evaluation, monitor side effects, determine optimal dosages, and identify the best method of administration—whether oral, intravenous, or injection. The goal is to understand how the treatment interacts with the human body.
"The rare ALS study excites me because it offers patients a potential last-resort treatment option," Dr. Truong shares.
Dr. Truong and his team pride themselves on being involved in every stage of clinical trials—from writing protocols and activating studies to dispensing medications and contributing to published results. "It’s incredibly satisfying to know that our work could lead to new treatment options for patients with limited or no alternatives," he adds.